The Pharma Letter1d
Celltrion unveils new post-hoc analyses of LIBERTY studies
South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...
The Pharma Letter2d
New batch of EC nods for Celltrion biosimilars
South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...
Hosted on MSN4d
Celltrion to buy back 100 bln won of stocks for enhanced shareholder value
Celltrion Inc., a major South Korean biopharmaceutical firm, said Wednesday it will buy back 100 billion won (US$69 million) worth of its own stocks to boost its shareholder value. Celltrion will ...
Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars
Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...
조선일보4d
Celltrion announces 100 billion won share buyback, starts market purchase tomorrow
Celltrion announces 100 billion won share buyback, starts market purchase tomorrow Celltrion to start market share buyback ...
centerforbiosimilars2d
EC Approves Celltrion Denosumab, Aflibercept Biosimilars
Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar ...
Business Wire4d
Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt ® (CT ...